Resultados de eficácia tavanic comp.

TAVANIC COMP. com posologia, indicações, efeitos colaterais, interações e outras informações. Todas as informações contidas na bula de TAVANIC COMP. têm a intenção de informar e educar, não pretendendo, de forma alguma, substituir as orientações de um profissional médico ou servir como recomendação para qualquer tipo de tratamento. Decisões relacionadas a tratamento de pacientes com TAVANIC COMP. devem ser tomadas por profissionais autorizados, considerando as características de cada paciente.



A eficácia de levofloxacina foi comprovada nos seguintes estudos: TAVANIC® 500 mg: (DAVIS, R. 1994) “Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.” “A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levoloxacin versus ceftriaxone and /or cefuroxime axetil in treatment of adults with community-acquired pneumonia.” (FILE, T. M. 1997); “Levofloxacin in the treatment of community acquired pneumonia.” (FILE, T.M. 1998); “Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections.” (CASELLAS, J.M. 1999); “Penetration of levofloxacin into lung tissue after oral administration to subjects undergoing lung biopsy or lobectomy.” (LEE, L. J. 1998); “Levofloxacina: una nueva generación de quinolonas para infecciones respiratórias.” (STAMBOULIAN, D. 1997); “A comparison of levofloxacin (LVFX) QD and amoxicillin-clavulanate (Amox/Clav) TID for the treatment of acute bacterial sinusitis.” (ADELGLASS, J. 1996). Outros estudos também demonstraram a eficácia de levofloxacina: “Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis.” (Habib, M.P. 1998); “A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection.” (Klimberg, I.W. 1998); “Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis.” (Richard, G.A. 1998); “Sparfloxacin and levofloxacin.” (Anon 1997); “Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults.” (Sydnor. T.A. 1998); “A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections.” (Nicodemo, A.C. 1998).